论文部分内容阅读
目的观察羟苯磺酸钙联合替米沙坦治疗早期糖尿病肾病的临床疗效及不良反应。方法将120例早期2型糖尿病肾病患者随机分为治疗组60例和对照组60例,对照组给予降糖、降低微量蛋白尿(使用替米沙坦)等常规治疗,治疗组在常规治疗的基础上给予羟苯磺酸钙。观察两组治疗前、后血肌酐(Scr)、尿素氮(BUN)、尿白蛋白排泄率(UAER)、血浆粘度(ηb)、纤维蛋白原(FN)、平均动脉压(MAP)及糖化血红蛋白(HbA1c)的变化及不良反应情况。结果两组治疗后UAER、ηb、FN、MAP值较治疗前均有改善(P<0.05),HbA1c略有改善,但较治疗前比较差异无统计学意义(P>0.05),BUN、Scr在治疗前后比较差异无统计学意义(P>0.05);治疗组UAER、ηb、FN值改善情况优于对照组(P<0.05);治疗后两组HbA1c、MAP水平相比差异无统计学意义(P>0.05),两组均未出现明显不良反应。结论羟苯磺酸钙联合替米沙坦治疗早期糖尿病肾病可以进一步降低UAER,且使用安全。
Objective To observe the clinical efficacy and side effects of calcium dobesilate and telmisartan in the treatment of early diabetic nephropathy. Methods A total of 120 patients with early type 2 diabetic nephropathy were randomly divided into treatment group (n = 60) and control group (n = 60). The control group was given conventional therapy such as hypoglycemic and microalbuminuria (telmisartan) Based on calcium dobesilate. The serum creatinine (Scr), blood urea nitrogen (BUN), urinary albumin excretion rate (UAER), plasma viscosity (ηb), fibrinogen (FN), mean arterial pressure (MAP) and glycosylated hemoglobin (HbA1c) changes and adverse reactions. Results The levels of UAER, ηb, FN and MAP in both groups were significantly improved (P <0.05) and HbA1c slightly after treatment, but there was no significant difference between before and after treatment (P> 0.05) The improvement of UAER, ηb and FN in the treatment group was better than that in the control group (P <0.05). There was no significant difference in the levels of HbA1c and MAP between the two groups after treatment (P> 0.05) P> 0.05), no obvious adverse reactions in both groups. Conclusion Calcium dobesilate combined with telmisartan in the treatment of early diabetic nephropathy can further reduce UAER, and safe to use.